CBD Life Sciences, Inc. (CBDL) Welcomes Major Political Endorsement for Cannabis Legalization
CBD Life Sciences Inc. (OTC PINK:CBDL) welcomes the Harris-Walz presidential ticket's endorsement of cannabis legalization, marking the first time a major U.S. presidential ticket has openly supported federal cannabis legalization. This political shift could significantly impact the cannabis and CBD industries, potentially leading to:
- A more regulated and transparent market
- Greater opportunities for innovation
- Expanded market access
- Enhanced research and development
- More refined products and clearer guidelines for consumers
CBDL's CEO, Lisa Nelson, expressed enthusiasm for the potential benefits this could bring to the industry and the company, aligning with CBDL's mission to deliver premium CBD products.
CBD Life Sciences Inc. (OTC PINK:CBDL) accoglie con entusiasmo il sostegno della candidatura presidenziale Harris-Walz alla legalizzazione della cannabis, segnando la prima volta che una candidatura presidenziale americana di rilievo ha apertamente sostenuto la legalizzazione federale della cannabis. Questo cambiamento politico potrebbe avere un impatto significativo sulle industrie della cannabis e del CBD, portando potenzialmente a:
- Un mercato più regolamentato e trasparente
- Maggiore opportunità per l'innovazione
- Accesso ampliato al mercato
- Sviluppo e ricerca migliorati
- Prodotti più affilati e linee guida più chiare per i consumatori
Il CEO di CBDL, Lisa Nelson, ha espresso entusiasmo per i potenziali benefici che questo potrebbe portare all'industria e all'azienda, in linea con la missione di CBDL di offrire prodotti CBD di alta qualità.
CBD Life Sciences Inc. (OTC PINK:CBDL) da la bienvenida al apoyo de la candidatura presidencial de Harris-Walz a la legalización del cannabis, marcando la primera vez que una candidatura presidencial importante en EE. UU. ha respaldado abiertamente la legalización federal del cannabis. Este cambio político podría tener un impacto significativo en las industrias del cannabis y del CBD, potencialmente llevando a:
- Un mercado más regulado y transparente
- Más oportunidades para la innovación
- Acceso ampliado al mercado
- Mejor investigación y desarrollo
- Productos más refinados y guías más claras para los consumidores
La CEO de CBDL, Lisa Nelson, expresó su entusiasmo por los beneficios potenciales que esto podría traer a la industria y a la empresa, alineándose con la misión de CBDL de ofrecer productos de CBD de primera calidad.
CBD 라이프 사이언스 Inc.(OTC PINK:CBDL)는 해리스-왈츠 대선 후보의 대마초 합법화 지지를 환영하며, 이는 주요 미국 대선 후보가 연방 대마초 합법화를 공개적으로 지지한 첫 번째 사례입니다. 이 정치적 변화는 대마초 및 CBD 산업에 상당한 영향을 미칠 수 있으며, 잠재적으로 다음과 같은 결과를 가져올 수 있습니다:
- 보다 규제되고 투명한 시장
- 혁신을 위한 더 많은 기회
- 확대된 시장 접근
- 향상된 연구 및 개발
- 소비자에게 더 정교한 제품과 명확한 가이드라인
CBDL의 CEO인 리사 넬슨은 이것이 산업과 회사에 가져올 수 있는 잠재적 이점에 대해 열정을 표현하며, CBDL의 목표인 프리미엄 CBD 제품 제공에 부합한다고 전했습니다.
CBD Life Sciences Inc. (OTC PINK:CBDL) accueille avec enthousiasme le soutien du ticket présidentiel Harris-Walz à la légalisation du cannabis, marquant la première fois qu'un ticket présidentiel américain majeur soutient ouvertement la légalisation fédérale du cannabis. Ce changement politique pourrait avoir un impact significatif sur les industries du cannabis et du CBD, pouvant conduire à :
- un marché plus régulé et transparent
- plus d'opportunités d'innovation
- un accès élargi au marché
- une recherche et développement améliorés
- des produits plus raffinés et des directives plus claires pour les consommateurs
La PDG de CBDL, Lisa Nelson, a exprimé son enthousiasme pour les bénéfices potentiels que cela pourrait apporter à l'industrie et à l'entreprise, s'alignant sur la mission de CBDL de fournir des produits CBD de haute qualité.
CBD Life Sciences Inc. (OTC PINK:CBDL) begrüßt die Unterstützung des Harris-Walz Präsidentschaftstickets für die Legalisierung von Cannabis, was das erste Mal ist, dass ein wichtiges US-Präsidentschaftsticket offen die bundesweite Legalisierung von Cannabis unterstützt. Diese politische Wende könnte erhebliche Auswirkungen auf die Cannabis- und CBD-Industrien haben und potenziell zu:
- einem stärker regulierten und transparenteren Markt
- größeren Innovationsmöglichkeiten
- ausgeweitetem Marktzugang
- verbesserter Forschung und Entwicklung
- verfeinerten Produkten und klareren Richtlinien für Verbraucher führen
Die CEO von CBDL, Lisa Nelson, äußerte Begeisterung über die potenziellen Vorteile, die dies für die Industrie und das Unternehmen bringen könnte, und stimmt mit CBDLs Mission überein, hochwertige CBD-Produkte anzubieten.
- Potential for expanded market access and opportunities due to political endorsement of cannabis legalization
- Possible increase in research and development opportunities in the CBD industry
- Potential for a more regulated and transparent market, benefiting established companies like CBDL
- None.
SCOTTSDALE, AZ / ACCESSWIRE / August 12, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), including its wholly owned subsidiary, The CBD Vault Inc., a rapidly expanding CBD company headquartered in Scottsdale, Arizona, proudly supports the recent endorsement of cannabis legalization by the Harris-Walz presidential ticket. This historic move marks the first time a major U.S. presidential ticket has openly advocated for the federal legalization of cannabis, a development that could significantly impact the future of the cannabis and CBD industries.
Lisa Nelson, President & CEO of CBDL, expressed her enthusiasm for the potential benefits this political shift could bring to the industry and the company. "The support for cannabis legalization by a major political ticket is a monumental step forward," said Nelson. "This endorsement not only reflects the changing public attitudes toward cannabis but also opens the door to a more regulated and transparent market. For CBDL, this means greater opportunities for innovation, expanded market access, and the ability to provide our customers with high-quality products in a more stable regulatory environment."
The Harris-Walz endorsement of cannabis legalization aligns with CBDL's mission to deliver premium CBD products that promote wellness and balance. With federal legalization, the industry could see a surge in research and development opportunities, leading to more refined products and clearer guidelines for consumers. This could also facilitate the expansion of CBDL's product offerings, including its newly launched kava and kratom shots, into new markets.
"Federal legalization would allow us to operate on a level playing field, bringing greater consistency and confidence to our customers," Nelson added. "We are committed to leading the way in this evolving industry, and we believe this political shift will enhance our ability to do so."
As the cannabis industry continues to grow and evolve, CBDL remains at the forefront, dedicated to providing innovative and effective CBD products. The company is excited about the possibilities that federal legalization could bring, not only for the industry but also for the millions of consumers who rely on cannabis and CBD for their wellness needs.
The CBD Vault Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. The CBD Vault has developed and is retailing/wholesale a full line of cannabidiol based & organic products including, Delta 8 & 10 Gummy's, Full Spectrum Tinctures & Gummy's, Pain Cream, Roll-on's, Salve, Full Pet Line, Pre-Rolls, Full Line of Spa Products, Sleep & Anxiety Edibles. The CBD Vault's products can be viewed and purchased on the Company's website www.thecbdvault.com.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is the significance of the Harris-Walz ticket endorsing cannabis legalization for CBDL stock?
How might federal cannabis legalization affect CBDL's product offerings?